Patients with apparently nonfunctioning adrenal incidentalomas may be at increased cardiovascular risk due to excessive cortisol secretion

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 8, 2014, Pages 2754-2762

  Androulakis, Ioannis I ^a,c   Kaltsas, Gregory A ^b   Kollias, Georgios E ^b   Markou, Athina C ^a   Gouli, Aggeliki K ^a   Thomas, Dimitrios A ^b   Alexandraki, Krystallenia I ^b   Papamichael, Christos M ^b   Hadjidakis, Dimitrios J ^c   Piaditis, George P ^a  

^a G GENNIMATAS GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENAL GLAND NEOPLASMS; CARDIOVASCULAR DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; FEMALE; GLUCOSE TOLERANCE TEST; HEMODYNAMICS; HUMANS; HYDROCORTISONE; INSULIN RESISTANCE; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84905841520     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-4064     Document Type: Article

References (46)

1. Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev. 2004;25:309-340.
2. Terzolo M, Stigliano A, Chiodini I, et al.AMEposition statement on adrenal incidentaloma. Eur J Endocrinol. 2011;164:851-870.
3. Barzon L, Sonino N, Fallo F, Palu G, Boscaro M. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol. 2003; 149:273-285.
4. Bovio S, Cataldi A, Reimondo G, et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest. 2006;29:298-302.
5. NIH state-of-the-science statement on management of the clinically inapparent adrenal mass ("incidentaloma"). NIH Consens State Sci Statements. 2002;19:1-25.
6. Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med. 2007;356:601-610.
7. Rossi R, Tauchmanova L, Luciano A, et al. Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J Clin Endocrinol Metab. 2000;85:1440-1448.
8. Bernini G, Moretti A, Iacconi P, et al. Anthropometric, haemodynamic, humoral and hormonal evaluation in patients with incidental adrenocortical adenomas before and after surgery. Eur J Endocrinol. 2003;148:213-219.
9. Garrapa GG, Pantanetti P, Arnaldi G, Mantero F, Faloia E. Body composition and metabolic features in women with adrenal incidentaloma or Cushing's syndrome. J Clin Endocrinol Metab. 2001; 86:5301-5306.
10. Terzolo M, Pia A, Alì A, et al. Adrenal incidentaloma: a new cause of the metabolic syndrome? J Clin Endocrinol Metab. 2002;87: 998-1003.
11. Peppa M, Koliaki C, Raptis SA. Adrenal incidentalomas and cardiometabolic morbidity: an emerging association with serious clinical implications. J Intern Med. 2010;268:555-566.
12. PeppaM, Boutati E, Koliaki C, et al. Insulin resistance and metabolic syndrome in patients with nonfunctioning adrenal incidentalomas: a cause-effect relationship? Metabolism. 2010;59:1435-1441.
13. Yilmaz H, Tütüncü NB, Sahin M. Two-year follow-up of thirty-two non-functional benign adrenal incidentalomas. J Endocrinol Invest. 2009;32:913-916.
14. Wagnerova H, Dudasova D, Lazurova I. Hormonal and metabolic evaluation of adrenal incidentalomas. Neoplasma. 2009;56:521-525.
15. Yener S, Genc S, Akinci B, et al. Carotid intima media thickness is increased and associated with morning cortisol in subjects with nonfunctioning adrenal incidentaloma. Endocrine. 2009;35:365-370.
16. Yener S, Baris M, Secil M, Akinci B, Comlekci A, Yesil S. Is there an association between non-functioning adrenal adenoma and endothelial dysfunction? J Endocrinol Invest. 2011;34:265-270.
17. Ermetici F, Dall'Asta C, Malavazos AE, et al. Echocardiographic alterations in patients with non-functioning adrenal incidentaloma. J Endocrinol Invest. 2008;31:573-577.
18. Ermetici F, Malavazos AE, Corbetta S, et al. Adipokine levels and cardiovascular risk in patients with adrenal incidentaloma. Metabolism. 2007;56:686-692.
19. Yener S, Comlekci A, Akinci B, et al. Non-functioning adrenal incidentalomas are associated with elevated D-dimer levels. J Endocrinol Invest. 2009;32:338-343.
20. Anderson TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol. 1995;26:1235-1241.
21. Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med. 1998;128:262-269.
22. Anderson TJ. Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol. 1999;34:631-638.
23. Lane HA, Smith JC, Davies JS. Noninvasive assessment of preclinical atherosclerosis. Vasc Health Risk Manag. 2006;2:19-30.
24. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-520
25. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106: 3143-3421.
26. Alexandraki KI, Makras P, Protogerou AD, et al. Cardiovascular risk factors in adult patients with multisystem Langerhans-cell histiocytosis: evidence of glucose metabolism abnormalities. QJM. 2008;101:31-40.
27. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39: 257-265.
28. Bergman RN, Prager R, Volund A, Olefsky JM. Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest. 1987;79: 790-800.
29. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85:2402-2410.
30. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462-1470.
31. Liddle GW. Tests of pituitary-adrenal suppressibility in the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab. 1960;20: 1539-1560.
32. Piaditis GP, Kaltsas GA, Androulakis II, et al. High prevalence of autonomous cortisol and aldosterone secretion from adrenal adenomas. Clin Endocrinol (Oxf). 2009;71:772-778.
33. American Diabetes Association. Standards of medical care in diabetes- 2013. Diabetes Care. 2013;36(Suppl 1):S11-S66.
34. Tauchmanovà L, Rossi R, Biondi B, et al. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab. 2002;87:4872-4878.
35. Chiodini I. Clinical review: Diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab. 2011;96:1223-1236.
36. Di Dalmazi G, Vicennati V, Rinaldi E, et al. Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study. Eur J Endocrinol. 2012;166: 669-677.
37. Vassilatou E, Vryonidou A, Michalopoulou S, et al. Hormonal activity of adrenal incidentalomas: results from a long-term follow-up study. Clin Endocrinol (Oxf). 2009;70:674-679.
38. Pivonello R, De Leo M, Vitale P, et al. Pathophysiology of diabetes mellitus in Cushing's syndrome. Neuroendocrinology. 2010; 92(Suppl 1):77-81.
39. Dall'Asta C, Barbetta L, Libé R, Passini E, Ambrosi B. Coexistence of 21-hydroxylase and 11 beta-hydroxylase deficiency in adrenal incidentalomas and in subclinical Cushing's syndrome. Horm Res. 2002;57:192-196.
40. Beuschlein F, BorgemeisterM, Schirra J, et al. Oral glucose tolerance testing but not intravenous glucose administration uncovers hyperresponsiveness of hypothalamo-pituitary-adrenal axis in patients with adrenal incidentalomas. Clin Endocrinol (Oxf). 2000;52:617-623.
41. Maser-Gluth C, Reincke M, Allolio B, Schulze E. Metabolism of glucocorticoids and mineralocorticoids in patients with adrenal incidentalomas. Eur J Clin Invest. 2000;30(Suppl 3):83-86.
42. Chiodini I, Morelli V, Salcuni AS, et al. Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J Clin Endocrinol Metab. 2010;95:2736-2745.
43. Toniato A, Merante-Boschin I, Opocher G, Pelizzo MR, Schiavi F, Ballotta E. Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study. Ann Surg. 2009;249:388-391.
44. Sereg M, Szappanos A, Toke J, et al. Atherosclerotic risk factors and complications in patients with non-functioning adrenal adenomas treated with or without adrenalectomy: a long-term follow-up study. Eur J Endocrinol. 2009;160:647-655.
45. Stewart PM. Is subclinical Cushing's syndrome an entity or a statistical fallout from diagnostic testing? Consensus surrounding the diagnosis is required before optimal treatment can be defined. J Clin Endocrinol Metab. 2010;95:2618-2620.
46. Chanson P, Salenave S. Metabolic syndrome in Cushing's syndrome. Neuroendocrinology. 2010;92(Suppl 1):96-101.